文献速递类风湿关节炎

ABT-122(靶向肿瘤坏死因子和白细胞介素-17A的双特异性双可变域免疫球蛋白)用于甲氨蝶呤应答不足的类风湿关节炎患者:一项随机双盲研究

ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.
PubMed 文献 · Arthritis Rheumatol · 2018-10-10

本研究纳入222例接受甲氨蝶呤治疗且未使用过生物制剂的活动性类风湿关节炎患者,随机接受ABT-122(60 mg每2周、120 mg每2周或120 mg每周)或阿达木单抗40 mg每2周治疗12周。主要终点第12周ACR20应答率在ABT-122各组分别为62%、75%和80%,阿达木单抗组为68%。ABT-122的安全性与阿达木单抗单用TNF抑制一致,120 mg每2周或每周的疗效与阿达木单抗40 mg每2周相比未显示有意义的差异。

要点

  • ABT-122各剂量组治疗中出现的不良事件与阿达木单抗组相似,未报告严重感染或全身性超敏反应。
  • 第12周ACR20应答率:ABT-122 60 mg每2周62%、120 mg每2周75%、120 mg每周80%,阿达木单抗40 mg每2周68%。
  • ABT-122 120 mg每2周或每周的疗效与阿达木单抗40 mg每2周相比未显示有意义的差异。

核心结论

  • 在12周研究期间,ABT-122双抑制TNF和IL-17A的安全性特征与阿达木单抗单用TNF抑制一致。
  • 在同时接受甲氨蝶呤的类风湿关节炎患者中,ABT-122 120 mg每2周或120 mg每周治疗12周的疗效与阿达木单抗40 mg每2周相比未显示有意义的差异。

研究设计与样本

  • 12周II期随机、双盲、阳性对照、平行组研究,纳入222例接受甲氨蝶呤治疗且未使用过生物制剂的活动性类风湿关节炎患者。
  • 患者随机接受ABT-122 60 mg每2周、120 mg每2周、120 mg每周或阿达木单抗40 mg每2周皮下给药。
  • 主要疗效终点为第12周达到美国风湿病学会20%改善标准(ACR20)的患者比例。

主要发现

  • 治疗中出现的不良事件在所有治疗组相似,ABT-122未报告严重感染或全身性超敏反应。
  • 第12周ACR20应答率:ABT-122 60 mg每2周组62%、120 mg每2周组75%、120 mg每周组80%,阿达木单抗40 mg每2周组68%。
  • 第12周ACR50应答率:ABT-122 60 mg每2周组35%、120 mg每2周组46%、120 mg每周组47%,阿达木单抗40 mg每2周组48%。
  • 第12周ACR70应答率:ABT-122 60 mg每2周组22%、120 mg每2周组18%、120 mg每周组36%,阿达木单抗40 mg每2周组21%。

关键数值与推荐

  • ACR20应答率:ABT-122 60 mg每2周62%、120 mg每2周75%、120 mg每周80%,阿达木单抗40 mg每2周68%。
  • ACR50应答率:ABT-122 60 mg每2周35%、120 mg每2周46%、120 mg每周47%,阿达木单抗40 mg每2周48%。
  • ACR70应答率:ABT-122 60 mg每2周22%、120 mg每2周18%、120 mg每周36%,阿达木单抗40 mg每2周21%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Tumor necrosis factor (TNF) and interleukin-17A (IL-17A) may independently contribute to the pathophysiology of rheumatoid arthritis (RA). This study sought to evaluate the safety and efficacy of ABT-122, a novel dual variable domain immunoglobulin targeting human TNF and IL-17A, in patients with RA who have experienced an inadequate response to methotrexate. METHODS: Patients with active RA who were receiving treatment with methotrexate and had no prior exposure to biologic agents (n = 222) were enrolled in a 12-week phase II randomized, double-blind, active-controlled, parallel-group study. Patients were randomized to receive either ABT-122 at dosages of 60 mg every other week, 120 mg every other week, or 120 mg every week or adalimumab at 40 mg every other week, administered subcutaneously. The primary efficacy end point was the proportion of patients achieving a ≥20% improvement response based on the American College of Rheumatology criteria for 20% improvement (ACR20) at week 12. RESULTS: Treatment-emergent adverse events were similar across all treatment groups, with no serious infections or systemic hypersensitivity reactions reported with ABT-122. ACR20 response rates at week 12 were 62%, 75%, and 80% with ABT-122 60 mg every other week, 120 mg every other week, and 120 mg every week, respectively, compared with an ACR20 response rate of 68% with 40 mg adalimumab every other week. The corresponding response rates for ACR50 and ACR70 improvement in the ABT-122 dose groups and adalimumab group were 35%, 46%, 47%, and 48%, respectively, and 22%, 18%, 36%, and 21%, respectively. CONCLUSION: Over the 12-week study period, dual inhibition of TNF and IL-17A with ABT-122 produced a safety profile consistent with that of adalimumb used for inhibition of TNF alone. The efficacy of ABT-122 over 12 weeks at dosages of 120 mg every other week or 120 mg every week was not meaningfully differentiated from that of adalimumab at a dosage of 40 mg every other week in patients with RA receiving concomitant methotrexate.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Genovese MC, Weinblatt ME, Aelion JA, et al. ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study. Arthritis Rheumatol. 2018. PMID: 29855172. doi:10.1002/art.40580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。